Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

山东省药用玻璃股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: ●山东鲁中投资有限责任公司（以下简称"鲁中投资"）持有山东省 药用玻璃股份有限公司（以下简称 "公司"）股份数量 129,380,980 股（无 限售流通股），占公司股份总数的 19.50%，为公司控股股东。 ●截至公告披露日，鲁中投资累计质押 40,360,000 股股份，占公司总 股本的 6.08%,占其所持本公司股份总数的 31.19%。 2025年12月30日公司收到鲁中投资转来的《股票质押式回购交易协议书 （两方）》，获悉其所持有公司的部分股份办理了质押，具体事项如下： | 股东名 | 是否为 | 本次质押股 | 是否 | 是否 | | 质押到 | 质权 | 占其所 | 占公司 | 质押融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | 为限 | 补充 | 质押起始日 | | ...

Core Viewpoint - Shandong Pharmaceutical Glass announced that its controlling shareholder, Luzhong Investment, holds 129.38098 million shares, accounting for 19.50% of the total share capital [1] Group 1 - Luzhong Investment pledged 33.06 million shares (25.55% of its holdings, 4.98% of the company's total share capital) to Zheshang Securities on December 29, 2025, with a pledge period until December 28, 2026 [1] - The financing from the pledged shares is intended for a loan to the Shandong Ruke Logistics investment project [1] - As of the announcement date, Luzhong Investment has cumulatively pledged 40.36 million shares, representing 6.08% of the company's total share capital and 31.19% of its total holdings [1]

Group 1 - In December, several leading pharmaceutical companies experienced significant executive changes, including Guoyao Holdings, BeiGene, and Zhendong Pharmaceutical [1][2] - Kexin Pharmaceutical announced the election of Li Hongfu as the chairman of its fourth board of directors on December 1 [1] - Kang En Bei reported that Jiang Yi resigned from multiple positions, including chairman, on December 6 due to work adjustments [1] Group 2 - WuXi AppTec appointed Tian Feng as the CEO and executive director, effective December 29, 2025 [2] - Alibaba Health announced the resignation of Zhu Shunyan as non-executive director and chairman, with current CEO Shen Difan taking over as chairman [2] - Sangfor Technologies reported the resignation of core technical personnel, Weng Zhibing, from all positions in its wholly-owned subsidiary on December 16 [2] Group 3 - Zhendong Pharmaceutical announced that Yang Lianmin resigned from his positions due to reaching retirement age on December 18 [2] - BeiGene appointed Dr. Wang Lai as president and global head of R&D, effective December 19 [2] - Guoyao Holdings announced Jin Bin as the new chairman on December 19, following the resignation of Zhao Bingxiang [2] Group 4 - Shijiazhuang Pharmaceutical Group reported that Zhang Cuilong stepped down from multiple roles, while Cai Lei was appointed as vice chairman and CEO on December 19 [3] - Weichuang Bio announced the appointment of Li Jianxun as general manager, while Chairman Lu Xianping stepped down from the general manager role on December 23 [3] - Shandong Pharmaceutical Glass reported that Chairman Hu Yonggang resigned from all positions due to age, with General Manager Zhang Jun taking over the chairman's responsibilities on December 24 [3]

证券代码：600529 证券简称：山东药玻 公告编号：2025-068 山东省药用玻璃股份有限公司 关于使用闲置募集资金购买理财产品的进展公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●委托理财受托方:中国工商银行股份有限公司 ●委托理财金额：人民币 40,000.00 万元 ●委托理财产品名称：区间累计型法人人民币结构性存款产品- 专户型 2025 年第 451 期 F 款 ●委托理财产品期限：92 天 ●履行的审议程序：公司于 2025 年 4 月 23 日召开了第十届董事 会第十七次会议和第十届监事会第十四次会议，并于 2025 年 5 月 16 日召开了公司 2024 年年度股东大会，审议通过了《关于使用闲置募 集资金购买理财产品的议案》，同意公司使用总额度不超过人民币八 亿元的暂时闲置募集资金进行购买安全性高、流动性好、期限不超过 12 个月（含）的保本型理财产品（包括但不限于协定性存款、结构 性存款、定期存款、通知存款、大额存单等），并在上述额度内滚动 使用，募集资金理财使用额度及授权的 ...

证券日报网讯12月25日，山东药玻（600529）在互动平台回答投资者提问时表示，除已披露信息，公司 目前未收到控股股东重组事宜相关进展通知；公司治理结构保持稳定，生产经营正常。 ...

证券代码：600529 证券简称：山东药玻 公告编号：2025-067 山东省药用玻璃股份有限公司（以下简称"公司"）非公开发行 股票募集资金投资项目之一"年产 5.6 亿只预灌封注射器扩产改造项 目"已实施完成，该项目募集资金已全部使用完毕，现将相关事项公 告如下： 山东省药用玻璃股份有限公司 关于部分募投项目结项并注销相关募集资金专项账 户的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●本次结项的募集资金投资项目: 年产 5.6 亿只预灌封注射器 扩产改造项目。 ●年产 5.6 亿只预灌封注射器扩产改造项目计划使用的募集资 金（含利息及理财收入等）已全部使用完毕，后续相关募集资金专项 账户将不再使用，为方便账户管理，公司对其进行注销，相关募集资 金监管协议将予以终止。 ●根据《上海证券交易所上市公司自律监管指引第 1 号—规范 运作》等相关规定，本次募投项目结项无需提交公司董事会、股东会 审议。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准山东省药用玻璃股份有限 公司非公开发行股票 ...

壹点企讯｜药用玻璃龙头山东药玻"换帅"，扈永刚因年龄辞任 热门评论我要评论 微信扫码 移动端评论 大众报业·齐鲁壹点55分钟前 12月23日，国内药用玻璃巨头山东药玻（600529.SH）发布公告称，董事长扈永刚因年龄原因申请辞去包括董事 长、董事及董事会下属专门委员会在内的所有职务，同时不再担任公司法定代表人。 壹点企讯｜药用玻璃龙头山东药玻"换帅"，扈永刚因年龄辞任 暂无评论 鲁ICP备15022957号-13 鲁公网安备 37010202002220号 鲁新网备案号201000101 电信增值业务许可证：鲁B2- 20120085 齐鲁晚报·齐鲁壹点 版权所有(C) All Rights Reserved 联系电话：0531-82625462邮箱：1790179766@qq.com ...

山东省药用玻璃股份有限公司 2026 年第一次临时股东会会议资料 证券代码：600529 证券简称：山东药玻 山东省药用玻璃股份有限公司 2026 年第一次临时股东会 会议资料 2026 年 1 月 8 日 1 山东省药用玻璃股份有限公司 2026 年第一次临时股东会会议资料 山东省药用玻璃股份有限公司 根据《公司法》和《山东省药用玻璃股份有限公司股东会议事规则》的有关 规定，为保证公司股东依法行使股东权利，本次股东会将采取现场会议和网络 投票方式表决，股东投票前请阅读本须知。 一、出席现场会议的股东需注意事项 1、现场会议由公司董事会召集召开，由董事、总经理张军先生主持。董事 会有义务维护股东合法权益，确保会议的正常秩序和议事效率。 2、股东及股东代表请按时有序进入指定会场，到场签名。 3、股东参加股东会，依法享有发言权、表决权等权利，请认真履行法定义 务，自觉遵守大会秩序，不得侵犯其他股东的权益。 4、现场工作人员有权对不符合会议要求的入场人员进行处理。 5、本次股东会现场会议采取记名投票方式进行表决，特请各位股东及其股 东代表或其委托代理人准确填写表决票：必须填写股东姓名或委托股东姓名， 同意请在"同意 ...

Group 1 - The chairman of Shandong Pharmaceutical Glass Co., Ltd., He Yonggang, has resigned, marking a significant personnel change shortly after the company was indirectly controlled by China National Pharmaceutical Group (Sinopharm) [1][19] - He Yonggang, aged 61, has had a long career with Shandong Pharmaceutical Glass, holding various key positions, and his resignation is attributed to age despite his term being set until May 2028 [2][20] - Zhang Jun, the current general manager, has been appointed to take over the chairman's responsibilities, bringing extensive production management and R&D experience to the role [2][20] Group 2 - Shandong Pharmaceutical Glass, established in 1970 and listed in 2002, specializes in the production of pharmaceutical glass packaging, covering a complete pharmaceutical packaging industry chain [4][22] - In June, Sinopharm and its Hong Kong subsidiary invested 2.449 billion yuan in Shandong Pharmaceutical Glass, acquiring a 51% stake in its controlling shareholder, thus indirectly controlling 19.5% of the company [4][22] - The company has achieved a nearly 90% market share in the domestic borosilicate molded bottle sector, which has been historically dominated by international giants [5][22] Group 3 - In 2024, Shandong Pharmaceutical Glass reported revenues of 5.125 billion yuan, a year-on-year increase of 287 million yuan, and a net profit of 904 million yuan, up 21.86% [5][22] - However, in the first three quarters of 2025, the company experienced a revenue decline of 11.1% to 3.4 billion yuan and a net profit drop of 24.7% to 543 million yuan, attributed to product homogenization and weak downstream demand [5][23] - The overall pharmaceutical distribution industry in China is experiencing a slowdown, prompting a trend towards consolidation among major players [14][30] Group 4 - Sinopharm is undergoing significant personnel changes across its pharmaceutical distribution companies, reflecting potential strategic shifts within the organization [6][13] - Recent leadership changes include the resignation of several key executives, indicating a response to the challenges faced by the company, including declining revenue growth [6][29] - Sinopharm is focusing on expanding its market presence by enhancing core customer relationships and increasing the share of high-value products in its overall revenue [31]